Oral Presentation Australasian Cytometry Society 43rd Annual Conference and Workshop

Immunophenotypic Evaluation of AML - Measurable Residual Disease Case Study (#47)

Malgorzata Gorniak 1
  1. Alfred Hospital, Melbourne, VIC, Australia

Malgorzata (Gosia) Gorniak-
I am currently employed as a Senior Scientist in the Clinical Flow cytometry at Alfred Hospital in Melbourne. I am responsible for the daily supervision of the flow cytometry diagnostic services provided by Haematology Department including quality assurance activities. In addition to the routine clinical services I support the unit and supervise the performance of the assays for Clinical Trials.

Clinical Flow at Alfred covers a wide range of test which include: lymphocytes subsets (T and B cells), CD34 counting and viability (fresh and frozen samples), FMH enumeration and the oncology immunophenotyping at diagnosis & disease monitoring that includes minimal residual disease.
I worked in the Clinical flow cytometry area for over 20 years and played a leading role in:
• Development and application of 5, 8 and 10 colour flow cytometry diagnostic tests (including high sensitivity minimal residual disease monitoring)
• Standardization of protocols including an active involvement in Custom cocktails for 10c AML, NHL, B-ALL
• Supervision of data analysing, involved in creating the gating strategies and implementation of Kaluza & Infinicyt software for MRD analysis
• Implementation of EuroFlow Next generation testing for MMMRD (Salamanca group)
• Winner in individual category for ‘Leading Innovation’ with recognition of our MRD work - Alfred Health in 2017
• Active in national assay guideline committees since 2016, involved in several of the taskforce committees currently updating the ACS Clinical Guidelines and international MM MRD proficiency analysis consortiums